NGM Biopharmaceuticals Inc expected to post a loss of 46  cents a share - Earnings Preview

NGM Biopharmaceuticals

03/05/2022 03:02

* NGM Biopharmaceuticals Inc  NGM.OQ   NGM.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 4
(estimated). 
    * The South San Francisco California-based  company is
expected to
report  a 4.9% increase in revenue to $22.631 million from
$21.58 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for NGM
Biopharmaceuticals
Inc is for a loss of 46 cents per share. For the same quarter
last year, the company reported a loss of 36 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $34​, above​ its last closing price
of $13.21. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.35       -0.36      -0.35     Beat    2.8
 Sep. 30 2021  -0.37       -0.35      -0.37     Missed  -5.7
 Jun. 30 2021  -0.34       -0.37      -0.48     Missed  -29.1​
 Mar. 31 2021  -0.42       -0.42      -0.36     Beat    14
 ​​Dec.        -0.51       -0.47      -0.40     Beat    15.1
 31 2020                                                
 Sep. 30 2020  -0.38       -0.38      -0.43     Missed  -13.6​
 Jun. 30 2020  -0.30       -0.31      -0.38     Missed  -21.4
 Mar. 31 2020  -0.26       -0.27      -0.28     Missed  -4.7
 This summary was machine generated May 3 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated